William Peters Sells 8,180 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William Peters sold 8,180 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the transaction, the chief financial officer directly owned 172,846 shares in the company, valued at $3,885,578.08. The trade was a 4.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals Stock Down 2.2%

AMPH stock opened at $19.98 on Thursday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $31.26. The stock has a market capitalization of $849.95 million, a price-to-earnings ratio of 11.82, a PEG ratio of 4.31 and a beta of 0.89. The business’s fifty day moving average price is $19.78 and its two-hundred day moving average price is $21.23. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71.

Get Amphastar Pharmaceuticals alerts:

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. On average, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.25 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after acquiring an additional 228,262 shares during the last quarter. TD Asset Management Inc grew its position in shares of Amphastar Pharmaceuticals by 1.6% during the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after acquiring an additional 31,160 shares during the period. State Street Corp grew its holdings in Amphastar Pharmaceuticals by 2.1% during the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock valued at $41,021,000 after purchasing an additional 31,044 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after acquiring an additional 40,536 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after purchasing an additional 363,216 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on AMPH shares. Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Wall Street Zen raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Wells Fargo & Company boosted their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, Barclays cut their target price on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $22.00.

Check Out Our Latest Stock Analysis on Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.

Featured Articles

• Five stocks we like better than Amphastar Pharmaceuticals
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.